On the other hand, miR-331-3p is reported to play an anti-cancer role in prostate cancer by targeting the RALA pathway [239] and ERBB-2 mediated androgen receptor signaling [240], colorectal cancer by targeting HER2 [241], NSCLC by targeting ErbB2, VAV2 and inhibiting epithelial to mesenchymal transition [242], glioblastoma and cervical cancer by regulating NRP-2 [243,244], ovarian cancer by targeting RCC2 [245], urothelial cancer by targeting NACC1 [246], and gastric cancer by targeting E2F1 [247]. Here, ERBB2 is linked to prostate cancer.